APA (7th ed.) Citation

L, A. d. L., DVS, C., MV, M., LC, H., WS, d. O., JQ, M., . . . J, G. (2026). Glucagon-Like Peptide-1 and Dual Incretin Agonists in Type 2 Diabetes with Peripheral Artery Disease: A Systematic Review and Meta-Analysis of Vascular, Cardiovascular, Metabolic, and Mortality Outcomes : Incretin Therapy in T2DM and PAD. Current diabetes reports, 26(1), . https://doi.org/10.1007/s11892-026-01619-4

Chicago Style (17th ed.) Citation

L, Araújo de Lucena, et al. "Glucagon-Like Peptide-1 and Dual Incretin Agonists in Type 2 Diabetes with Peripheral Artery Disease: A Systematic Review and Meta-Analysis of Vascular, Cardiovascular, Metabolic, and Mortality Outcomes : Incretin Therapy in T2DM and PAD." Current Diabetes Reports 26, no. 1 (2026). https://doi.org/10.1007/s11892-026-01619-4.

MLA (9th ed.) Citation

L, Araújo de Lucena, et al. "Glucagon-Like Peptide-1 and Dual Incretin Agonists in Type 2 Diabetes with Peripheral Artery Disease: A Systematic Review and Meta-Analysis of Vascular, Cardiovascular, Metabolic, and Mortality Outcomes : Incretin Therapy in T2DM and PAD." Current Diabetes Reports, vol. 26, no. 1, 2026, https://doi.org/10.1007/s11892-026-01619-4.